All In Biotech

Drug Trial Radar · NCT01242514

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Apr 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,917

Actual

Start

Jan 2011

Primary completion

Jan 2015

Study completion Jan 2015

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 17, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients with rheumatoid arthritis (RA).

Conditions

  • Rheumatoid Arthritis

Interventions

  • FostamatinibDrug

    Fostamatinib 100mg twice daily

  • FostamatinibDrug

    Fostamatinib 150mg once daily

  • FostamatinibDrug

    Fostamatinib 100mg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Who Had at Least 1 Adverse Event in Any CategoryTime frame: Entry in extension to end of study (variable duration; maximum 109 weeks)

Locations

308 sites in 31 countries. Site status is shown where the registry gives one.

  • Research Site

    Anniston, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Tuscaloosa, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Mesa, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Fountain Valley, California

  • Research Site

    Huntington Beach, California

  • Research Site

    La Jolla, California

  • Research Site

    Long Beach, California

  • Research Site

    Palo Alto, California

  • Research Site

    Roseville, California

  • Research Site

    Santa Maria, California

  • Research Site

    Santa Monica, California

  • Research Site

    Torrance, California

  • Research Site

    Upland, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    Danbury, Connecticut

  • Research Site

    Trumbull, Connecticut

  • Research Site

    Lewes, Delaware

  • Research Site

    Boca Raton, Florida

  • Research Site

    Brandon, Florida

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Fort Lauderdale, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Palm Harbor, Florida

  • Research Site

    Pinellas Park, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Tavares, Florida

  • Research Site

    Venice, Florida

  • Research Site

    Zephyrhills, Florida

Showing 40 of 308 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.